Diabetes. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Quercetin, an oral 250-mg dietary supplement, once daily, for 8 weeks. Intervention 2: Acetate cellulose, an oral 250-mg dietary supplement, once daily, for 8 weeks.
Placebo
Quercetin, an oral 250-mg dietary supplement, once daily, for 8 weeks
Acetate cellulose, an oral 250-mg dietary supplement, once daily, for 8 weeks
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age range 35-60 years; having controlled diabetes (no need for changes in oral hypoglycemic medication during the study or having HbA1C <7%, pre-prandial capillary blood glucose <150 mg/dl and peak postprandial capillary blood glucose <180 mg/dl); maximum period of 10 years from the diagnosis of the disease; having normal blood pressure (systolic and diastolic blood pressure: <120 mmHg and <80 mmHg, respectively). Exclusion criteria: smoking and/or drinking alcohol; having documented liver/kidney and/or lung diseases, kidney stone or any other type of chronic and/or acute inflammatory disorder; taking any lipid lowering and/or hypotensive medication and multi-vitamin mineral supplements; having documented clinically significant secondary complication of the disease (i.e. diabetic retinopathy, nephropathy and neuropathy)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FBS. Timepoint: Baseline and at the endpoint (after 8 weeks) of the trial. Method of measurement: mg/dl, by using auto-analyzer.;Insulin. Timepoint: Baseline and at the endpoint (after 8 weeks) of the trial. Method of measurement: microU/ml, by using an ELISA kit.;Hb A1C. Timepoint: Baseline and at the endpoint (after 8 weeks) of the trial. Method of measurement: percentage(%), by using HPLC method.;Triglyceride. Timepoint: Baseline and at the endpoint (after 8 weeks) of the trial. Method of measurement: mg/dl, by using auto-analyzer.;Total-cholesterol. Timepoint: Baseline and at the endpoint (after 8 weeks) of the trial. Method of measurement: mg/dl, by using auto-analyzer.;LDL-cholesterol. Timepoint: Baseline and at the endpoint (after 8 weeks) of the trial. Method of measurement: mg/dl, by using auto-analyzer.;HDL-cholesterol. Timepoint: Baseline and at the endpoint (after 8 weeks) of the trial. Method of measurement: mg/dl, by using auto-analyzer.;Ox-LDL. Timepoint: Baseline and at the endpoint (after 8 weeks) of the trial. Method of measurement: U/L, by using ELISA kit.;Total Antioxidant Capacity. Timepoint: Baseline and at the endpoint (after 8 weeks) of the trial. Method of measurement: nmol/mL, by using an ELISA kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyedeh Maryam Abdollahzadeh
Shiraz University of Medical Sciences
Outcome results
None listed